Quantinno Capital Management LP Has $5.51 Million Position in Haleon plc (NYSE:HLN)

Quantinno Capital Management LP raised its holdings in shares of Haleon plc (NYSE:HLN - Free Report) by 17.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 577,518 shares of the company's stock after acquiring an additional 87,557 shares during the period. Quantinno Capital Management LP's holdings in Haleon were worth $5,510,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Sierra Ocean LLC acquired a new position in shares of Haleon during the fourth quarter valued at $26,000. Geneos Wealth Management Inc. bought a new position in Haleon in the 4th quarter valued at about $35,000. FIL Ltd increased its stake in Haleon by 45.7% during the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after buying an additional 1,270 shares during the period. Spire Wealth Management bought a new stake in shares of Haleon during the 4th quarter worth about $39,000. Finally, Addison Advisors LLC lifted its stake in shares of Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after acquiring an additional 1,106 shares during the period. Institutional investors and hedge funds own 6.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HLN. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective on the stock in a research note on Friday, May 9th. Barclays reiterated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Finally, HSBC reiterated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.25.

Haleon Price Performance

Shares of NYSE:HLN traded up $0.08 on Wednesday, reaching $11.10. 21,467,594 shares of the company traded hands, compared to its average volume of 8,132,053. The stock has a market capitalization of $50.02 billion, a PE ratio of 32.63, a P/E/G ratio of 2.82 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company's 50 day moving average is $10.25 and its 200-day moving average is $9.88. Haleon plc has a fifty-two week low of $8.25 and a fifty-two week high of $11.15.

Haleon (NYSE:HLN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. As a group, analysts anticipate that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently disclosed a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This is a positive change from Haleon's previous -- dividend of $0.05. This represents a yield of 1.6%. Haleon's dividend payout ratio is currently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.